First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Readers say diversification and exposure to good companies call for looking beyond the U.S.
Roche Receives FDA Approval for cobas® KRAS Mutation Test
Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO
Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.
These top managers continue to focus on higher-quality dividend-paying stocks in a market that has become more volatile of late.
We see attractive growth opportunities for the ophthalmology market.
Success starts with teamwork for this year's winners.
Continued technology advancements and market expansion support Illumina's narrow moat.